Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
Hosted on MSN42m
NVO Stock Rises as New Obesity Drug Shows Superior Weight LossShares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback